Quotient Bioresearch Acquires Edinburgh Clinical Research Facility from Charles River Laboratories
News May 21, 2009
Quotient Bioresearch Limited (Quotient) has announced that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient.
The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new strategic business unit within Quotient - Quotient Clinical.
With a long heritage in early development services, the Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles to offer a suite of integrated services stretching from First-in-Human (FIH) through to Phase 2a patient studies.
Founded almost 20 years ago, the Edinburgh clinical unit is an industry leader in FIH studies. It was awarded Supplementary Accreditation status by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2009, demonstrating its experience and capabilities to conduct FIH trials for small molecules and biologics.
Quotient Clinical will have a workforce of approximately 160 medical, scientific and clinical staff across the two facilities in Edinburgh and Nottingham. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.
Paul Cowan, Chairman and CEO of Quotient comments, “The creation of Quotient Clinical represents the next step in expanding the range of specialized services we offer pharmaceutical and biotech customers worldwide. We are delighted to have completed the acquisition of the Charles River Edinburgh clinical facility. With the Inveresk heritage we are bringing a world-class facility and clinical experience to Quotient Clinical.”
Quotient Clinical will be headed by Mark Egerton, formerly Chief Executive Officer of Pharmaceutical Profiles. “We will continue to build on the innovative approaches we developed at Pharmaceutical Profiles to increase the effectiveness of early development processes. Combined with the Phase I/2a expertise of the Charles River Edinburgh clinical unit, our approach to integrating flexible drug product manufacture into clinical trials will enable us to deliver significant benefits to our customers.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE